Core Viewpoint - The article emphasizes the growing recognition of obesity as a medical condition rather than a personal failing, highlighting the need for systemic intervention and support in managing weight and related health issues [3][4][7]. Group 1: Current State of Obesity in China - As of 2018, the overweight rate among adults in China was 34.3%, with an obesity rate of 16.4%, translating to approximately 182 million adults suffering from obesity [3]. - Public perception often misattributes obesity to personal lack of discipline, which complicates access to medical support for those affected [3][9]. Group 2: Policy and Medical Response - The National Health Commission and the National Administration of Traditional Chinese Medicine plan to establish weight management clinics in hospitals by June 2025, aiming for comprehensive coverage [4]. - The "Weight Management Year" initiative is part of a broader public health strategy to enhance awareness and skills related to weight management across the population [11][21]. Group 3: Changing Perceptions and Treatment Approaches - A significant portion of the public (84%) attributes obesity to personal self-control issues, while only about 60% recognize genetic and environmental factors as contributors [7]. - New medications, such as GLP-1 receptor agonists, are changing the treatment landscape for obesity, allowing for more effective management of weight and associated metabolic conditions [16][18]. Group 4: Integrated Weight Management Systems - The article discusses the establishment of integrated weight management systems in hospitals, which include a multidisciplinary approach involving doctors, nutritionists, and health managers [12][14]. - The "1+3+N" model implemented in hospitals aims to provide comprehensive care from screening to treatment and management, reflecting a shift towards a more collaborative healthcare approach [12][14]. Group 5: Community and Societal Engagement - The article highlights the importance of community involvement in weight management, advocating for initiatives that promote healthy lifestyles at the family, community, and workplace levels [14][21]. - Public support for integrating obesity prevention into national health strategies is strong, with many favoring practical interventions like community fitness facilities [19][22].

Core Viewpoint - The article highlights a significant global diabetes crisis, with the number of adult diabetes patients skyrocketing from 200 million in 1990 to 828 million in 2022, marking an increase of over 300% [4][5][6]. Global Diabetes Trends - The study analyzed data from 1.41 billion participants across 1108 population-representative studies, revealing that diabetes has transitioned from a "disease of affluence" to a widespread public health challenge affecting all demographics [5][6]. - The highest prevalence of diabetes is found in low- and middle-income countries, particularly in regions such as Southeast Asia, South Asia, the Middle East, North Africa, and Latin America [4][5][7]. Patient Distribution and Demographics - As of 2022, the top three countries with the highest number of diabetes patients are India (212 million), China (148 million), and the United States [6]. - The age-standardized prevalence of diabetes in 2022 shows a slight male predominance (14.3%) over females (13.9%), although the total number of female patients (420 million) exceeds that of males (408 million) [6]. Treatment Gaps - Alarmingly, 59% of diabetes patients aged 30 and above globally did not receive any treatment in 2022, a 3.5-fold increase since 1990 [9][10]. - India and China are identified as the countries with the highest number of untreated patients, with India having 133 million untreated cases compared to China's 78 million [9]. Regional Treatment Disparities - Treatment coverage has improved in Central and Western Europe and some Latin American countries, while regions like sub-Saharan Africa and South Asia show little to no improvement, with some African countries having treatment coverage below 10% [9][10]. - High-income countries generally maintain treatment coverage above 55%, contrasting sharply with the dire situation in many low-income regions [9]. Recommendations for Improvement - The article emphasizes the urgent need for systemic reforms in diabetes care, particularly in low- and middle-income countries, to enhance early screening and standardized treatment [11]. - It suggests that expanding insurance coverage and strengthening primary healthcare systems are critical steps to address the growing diabetes burden [11].

Core Viewpoint - The article discusses the safety concerns and recommendations regarding the use of GLP-1 medications during pregnancy and breastfeeding, highlighting the need for caution and further research in this area [1][3]. Group 1: Research on GLP-1 Medications and Pregnancy - A large study published in January 2024 in JAMA Internal Medicine tracked around 50,000 children born to mothers with type 2 diabetes who used GLP-1 or insulin in early pregnancy, finding no increased risk of congenital defects compared to insulin use [5]. - Another study published in 2023 reviewed 39 independent studies on the effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and breastfeeding, concluding that there is extremely limited information on their safety [6]. Group 2: Risks Associated with GLP-1 Use During Pregnancy - Potential risks of GLP-1 medications during pregnancy may include miscarriage, low birth weight, and congenital defects, primarily due to their impact on maternal food intake and weight gain [6][7]. - Although concerns are mainly based on animal studies, the lack of human research has led to recommendations for discontinuation during pregnancy [7]. Group 3: Recommendations for Women Planning to Become Pregnant - Women are advised to stop using any GLP-1 medications at least two months before attempting to conceive, along with adopting additional preconception lifestyle measures [8]. - The American Diabetes Association recommends insulin as the preferred medication for managing diabetes during pregnancy, while other diabetes medications like metformin and glipizide are not first-line treatments due to their placental transfer [7][8]. Group 4: Breastfeeding Considerations - There is insufficient research to determine the safety of GLP-1 medications during breastfeeding, leading to recommendations against their use during this period [9][10].

整理 | GLP1减重宝典内容团队 7月1日，专注于肥胖、糖尿病及罕见病口服疗法的临床阶段生物制药公司 Syntis Bio 宣布，已成功完成3300万美元A轮超额认购融资。本轮融 资由 Cerberus Ventures 领投，Mansueto Investments、Woori Venture Partners 和 Apollo Labs 等新投资方加入，早期支持者 BOLD Capital Partners、W.R. Berkley Corporation、Safar Partners、Portal Innovations、Colorcon Ventures 及 Cerity Partners Ventures 也继续加码投资。 创始人之一Professor Robert S. Langer 是美国麻省理工学院（MIT）David H. Koch 生物工程研究所的联合创始人兼资深教授。他是世界顶尖 的生物医学工程学者之一，以在药物递送系统和组织工程领域的开创性工作闻名。Langer 教授拥有超过1,400项已授权或申请中的专利，其技 术已促成40多家生物科技公司的发展，是现代生物医药产业最具影响力的科学 ...

肥胖已成为21世纪最严峻的全球公共卫生危机之一，其蔓延速度令人震惊。据世界卫生组织最新统计，过去半个世纪全球超重人口激增 近三倍，这一数字仍在持续攀升。 传统观点将肥胖简单归结为能量失衡——即"摄入过多而消耗不足"，这种理论主导了数十年的肥胖防治策略。然而，国际知名代谢研究 专家Ba r ba r a E. Co r ke y教授的最新研究发现，肥胖的成因远比我们想象的复杂。她的突破性研究指出，现代饮食中普遍存在的食品添 加剂、环境内分泌干扰物等因素，可能正在悄然改变人体的代谢调控机制。 这些隐藏在日常生活背后的"代谢干扰因子"，正以我们尚未完全理解的方式，重塑着人类的能量代谢平衡系统。这一理论为理解全球肥 胖流行提供了全新视角，也解释了为何单纯依靠"少吃多动"往往难以取得理想效果。 随着研究的深入，科学家们逐渐意识到，对抗肥胖需要从更宏观的环境因素和更微观的分子机制双重维度着手。这场关乎人类健康的持 久战，正在揭开其复杂性的冰山一角。 这些被称为"肥胖诱导物"的化学分子广泛存在于日常生活的各个层面： 从充满添加剂的超加工食品到被工业污染的饮用水，从城市空 气中的汽车尾气到日常使用的塑料制品， 它们通过食物链 ...

Core Viewpoint - The article emphasizes the importance of weight management as a national strategy in China, particularly in the context of chronic disease prevention and control, highlighting the launch of a three-year "Weight Management Year" initiative starting in 2024 [3][9]. Group 1: National Strategy and Policy - In 2024, weight management will be elevated to a national strategic level, with a three-year initiative launched by the National Health Commission in collaboration with 16 other departments [3]. - By April 2025, the "Healthy Weight Management Action" will be officially included in the "Healthy China 2030 Action" overall plan, showcasing a comprehensive policy framework at national, provincial, and municipal levels [3][11]. Group 2: Chronic Disease Burden - Chronic diseases account for over 70% of the total disease burden in China, with abnormal weight being a significant health risk [7]. - The overweight rate among adults has reached 50.7%, with central obesity affecting over 280 million people, and the hidden obesity rate (normal BMI but high body fat) at 30% [7]. - Overweight and obesity are linked to a 40%-200% increased risk of 13 types of cancer, and the obesity rate among adolescents has increased 11 times over the past 20 years [7]. Group 3: Community and Individual Responsibility - The initiative calls for a collaborative effort among government, industry, organizations, and individuals to create a supportive environment for weight management [10]. - The government aims to curb the rising obesity rate and increase public health literacy from 18% in 2024 to 30% by 2030 [11]. Group 4: Market Opportunities - By 2025, the health weight management industry is expected to experience explosive growth, creating a new health consumption market worth over 380 billion yuan, driven by policy support, technological advancements, and consumer upgrades [12]. - Notable weight loss brands are emerging, gaining popularity among health-conscious consumers [12]. Group 5: Family and Personal Actions - Families are encouraged to adopt tools for weight management and emphasize the importance of monitoring children's health [13]. - Individuals are urged to understand the risks of overweight and obesity and to manage their weight through informed dietary, exercise, and lifestyle choices [14].

整理 | GLP1减重宝典内容团队 替尔泊肽是一种GLP-1/GIP双靶点激动剂，而司美格鲁肽则是一种GLP-1受体激动剂。虽然两者都能帮助减重，但它们的分子结构、作用机制 和临床效果各有不同。替尔泊肽通过同时激活GLP-1和GIP受体发挥作用，而司美格鲁肽主要通过激活GLP-1受体来实现减重效果。 ▍不建议同时使用 替尔泊肽和司美格鲁肽都是GLP-1受体激动剂，用于体重管理，但它们的作用机制和临床应用有所不同。根据《2024年肥胖症诊疗指南》发布 的内容，这两种药物在中国均已获批用于成年原发性肥胖症患者的减重治疗。然而，由于两者的作用机制不同，混合使用这两种药物并不推 荐，因为可能会增加不良反应的风险，并影响药物效果。 ▍结构与机制的差异 在临床实践中，医生会根据患者的具体情况以及药物的特性来选择最合适的治疗方案。通常情况下，司美格鲁肽被推荐作为基础治疗，适用于 那些饮食控制不足的肥胖人群。若司美格鲁肽效果不佳或副作用较大，替尔泊肽可作为替代选择。 然而，混合使用这两种药物可能带来不可预测的风险和副作用，因此并不推荐。患者应在医生的指导下，严格按照药物说明书及专业医师的建 议使用其中一种药物，并定期监测药物 ...

整理 | GLP1减重宝典内容团队 | 16 | CXSL2500321 | XW003注射液 | 杭州先为达生物科技股 | 本品拟用于12~17岁青 | | --- | --- | --- | --- | --- | | | | | 份有限公司 | 少年肥胖患者体重管理 | | 17 | CXSL2500320 | XW003注射液 | 杭州先为达生物科技股 | 本品拟用于12~17岁青 | | | | | 份有限公司 | 少年肥胖患者体重管理 | 近日，国家药品审评中心（CDE）官网信息显示，先为达自主研发的 XW003 注射液已获批在青少年人群中开展临床试验，适应症为 12 至 17 岁肥胖青少年的体重管理。 XW003（通用名：埃诺格鲁肽注射液，原名：伊诺格鲁肽）是一款具有全球创新性质的 GLP-1 受体激动剂，具备 cAMP 偏向性，由先为达独 立开发。与传统 GLP-1 激动剂不同，XW003 选择性激活 cAMP 信号通路，同时减少 β-arrestin 的激活，有望因此提升治疗效果并带来更多代 谢获益。 目前，XW003 已完成三项 III 期临床试验，并已就成人 2 型糖尿病的血糖控制及成人 ...

Core Viewpoint - Diabetes is manageable through monitoring key health indicators and implementing scientific interventions, which can significantly reduce the risk of complications and improve quality of life [4][21]. Group 1: Key Health Indicators - The article introduces 12 essential health indicators for diabetes management, including blood sugar, blood pressure, and blood lipids, which can be monitored at home or through regular check-ups [4][16]. - Fasting blood sugar should be maintained between 4.4-7.0 mmol/L, with levels above 7.0 mmol/L indicating a need for adjustment in nighttime glucose control strategies [5]. - Blood pressure should be strictly controlled below 130/80 mmHg, especially for those with kidney disease, while LDL-C should be below 2.6 mmol/L [6]. Group 2: Metabolic Management - Body Mass Index (BMI) should ideally be maintained between 18.5-24.0, and waist circumference should be less than 90 cm for men and 85 cm for women [7]. - Regular monitoring of urine microalbumin (less than 30 mg/24h) is crucial for early detection of kidney damage [7]. - Annual eye examinations and foot nerve assessments are essential, as these often provide early warnings of complications [7][9]. Group 3: Specific Health Monitoring - Liver function should be monitored regularly, with ALT and AST levels ideally below 40 U/L, as 70% of diabetes patients may have fatty liver [10]. - Uric acid levels should be controlled below 420 μmol/L for men and 360 μmol/L for women to prevent complications [11]. - Cardiovascular health screening is vital, as diabetes patients have a 2-4 times higher risk of coronary heart disease [12]. Group 4: Management Strategies - A scientific lifestyle management system is crucial for controlling diabetes indicators, emphasizing a diet low in glycemic index, saturated fat, and sodium, while high in dietary fiber [18]. - Exercise recommendations include daily activity for at least 30 minutes, five days a week, with heart rates maintained at a safe level [19]. - Medication should be individualized, with metformin as the first-line treatment, and regular assessments every three months to adjust treatment plans based on HbA1c results [19]. Group 5: Diagnosis Standards - Diabetes diagnosis requires strict laboratory testing standards, including fasting blood sugar levels and glucose tolerance tests [20]. - For asymptomatic individuals, a single abnormal test is insufficient for diagnosis; confirmation through repeat testing is necessary [20]. Group 6: Conclusion - Continuous monitoring and management of blood sugar and related indicators are essential to prevent complications associated with diabetes, ensuring a healthier life [21].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 自去年起，减重诊疗对公立医院来说，已经从"可选项"变成了必须认真布局的新任务。 2024年6月，国家卫生健康委联合16个部门发布了《"体重管理年"活动实施方案》，明确鼓励有条件的医疗卫生机构设立体重管理门诊。政策 要求，国家卫生健康委、国家中医药局直属及管理医院，以及各省（区、市）属综合医院、儿童医院、中医医院，要在2025年6月底前基本实 现体重管理门诊的全覆盖。 随着政策"最后期限"临近，各地医院纷纷加快步伐，地方卫健委也陆续公布本地体重管理门诊的建设进展。 据公开报道，北京已有119家二级及以上医院和76家基层卫生服务中心可提供体重管理服务；广州有63家医院开设了体重管理门诊；浙江全省 249家二级及以上医疗机构已设立体重管理门诊，累计服务患者超过20万人次；四川则有446家医疗机构开设了体重管理或肥胖防治门诊。 目前，外科、内分泌、营养、中医等多个科室纷纷进军减重领域，院内形成了激烈的"赛马"态势，有的医院甚至设立了七八个减重门诊，科室 之间竞 ...